Goodwin-Led Gene Therapy Co. Nabs $150M Via PIPE
Gene therapy company Orchard Therapeutics, guided by Goodwin Procter LLP, said Friday it was injected with $150 million in a private investment in public equity, or PIPE, deal anchored by roughly...To view the full article, register now.
Already a subscriber? Click here to view full article